A retrospective assessing clinical outcome of first-generation EGFR-TKI first-line treatment and the allele frequency of EGFR T790M in plasma samples,exploring the benefits afforded by subsequent osimertinib treatment.
Latest Information Update: 21 Sep 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Sep 2021 New trial record
- 15 Sep 2021 Results published in the International Journal of Clinical Practice